Eye

RheumNow Podcast square

Consequences of TNF inhibition (3.18.2022)

Jack Cush, MD
Mar 18, 2022

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past

Read Article
2021 approved Efgartigimod (Vyvgart) for myasthenia gravis: (binds neonatal Fc receptor, stops Ig recirculation): pts w/ AChR Abs respond best (68% vs 30%). Common AEs include URI, UTI, HA; other AE: eyelid swelling, rash, and SOB. https://t.co/wQKZuAlXoR

Links:

Dr. John Cush @RheumNow( View Tweet )

Jan 31, 2022
Genes and Obesity Tied to Higher Gout Risk in Women Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found.https://t.co/vLR8GJC9qf https://t.co/6Scc5c0dUU

Links:

Dr. John Cush @RheumNow( View Tweet )
Dec 13, 2021
uveitis eye iritis

New Insights into Uveitis in Spondyloarthritis

Antoni Chan, MD, PhD
Dec 01, 2021

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis. Being such a prevalent EAM in

Read Article
Uveitis and Prevalence of Psoriasis in axSpA: Dr. Robert Chao ( @doctorRBC) discusses the best SpA abstracts he saw at the #ACR21 annual meeting: abstracts #1324 and #1311.https://t.co/6zARkjsoCg

Links:

Dr. John Cush @RheumNow( View Tweet )

Nov 23, 2021
Fr AQUILA study: #Uveitis status in AS or PsA pts given SEC 👁‍🗨3 pts w/o uveitis at BL developed new onset uveitis during study 👁‍🗨Most pts w/uveitis at BL - status remained unchanged or improved 👁‍🗨SEC did not ⬆ risk of uveitis @RheumNow #ACR21 abs1738 https://t.co/IGUpgXBLvt
sheila @RHEUMarampa( View Tweet )
Nov 09, 2021
uveitis eye iritis

New Insights into Uveitis in Spondyloarthritis

Antoni Chan, MD, PhD
Nov 09, 2021

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis. Being such a prevalent EAM in

Read Article
Adults with #JIA #uveitis are still affected into adulthood. @Mara_Becker discusses visual outcomes #ACR21 https://t.co/ZBjw1CfSmv
Sheila Angeles-Han @STHanMD( View Tweet )
Nov 08, 2021
#Uveitis is the most ⬆ freq xtra-articular manifestation in axSpA. What factors are assoc'd w/AAU attacks? 👁‍🗨Active disease 👁‍🗨History of AAU Bottomline: Treat axSpA, treat uveitis = better outcomes. @RheumNow #ACR21 abs1314 https://t.co/O0kHulwJoP
sheila @RHEUMarampa( View Tweet )
Nov 08, 2021
axSpA and Uveitis Uveitis 🔼 in HLA-B27; Disease duration; Latin American pts 🔽 in Psoriasis ⭐️Uveitis was not significantly different in axSpA vs pSpA Recurrent Uveitis 🔼disease duration and body mass index (BMI) Abst #1307 #ACR21 @Rheumnow https://t.co/QDg8tOPgir
swethaann23 @swethaann23( View Tweet )
Nov 08, 2021
Knowledge Bowl at #ACR21 ⭐️Which HLA allele confers an increased risk for anterior uveitis and inflammatory sacroillitis? ➡️HLA-B27 @RheumNow

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Nov 08, 2021
Low incidence of GI-related serious AE in pooled 1 year data from VOY1&2 and DISC1&2 trials of Guselkumab for PsA/PsO treatment ⭐️no new onset IBD or exacerbation of IBD ⭐️no uveitis, infections, TB Abs#1342 #ACR21 @RheumNow https://t.co/x3OmLgInV0

Links:

Robert B Chao, MD @doctorRBC( View Tweet )

Nov 08, 2021
ACR Best

ACR21 Best Abstracts - Day 2

Jack Cush, MD
Nov 07, 2021

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

Read Article
Image of Takayasu's retinopathy (compared to normal) presented by John Stone #ACR21 . I'm no eye doctor, but this cannot be good. @RheumNow https://t.co/rjoQZ8TGDz
Richard Conway @RichardPAConway( View Tweet )
Nov 07, 2021
⭐️Imaging of the SIJ in psoriatic axSpA is similar to axSpA associated with iritis or colitis! Abst#0902 (https://t.co/f55Vfi1LSS) #ACR21 @RheumNow https://t.co/UCXrwPiyhh

Links:

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Nov 07, 2021
#ClinicalPearl Leflunomide for chronic CMV retinitis failing antiviral Rx? Suppresses inflammation & Arava May have antiviral properties. Didn’t know it. Kolfenbach & Palestine 6S117 eye opening experiences #ACR21 @RheumNow

Janet Pope @Janetbirdope( View Tweet )

Nov 06, 2021
#ClinicalPearl Joint clinic btwn ophthalmology & #rheumatology helps make dx & Rx work. #ACRBest #ACR21 see work up of inflammatory eyes disease. All are allowed one acute ant uveitis- ? dogma maybe work up all. 6S117 https://t.co/Wwdv3N66HS
Janet Pope @Janetbirdope( View Tweet )
Nov 06, 2021
#ClinicalPearl. ‘my eye hurts-what’s going on!’ Dr Palestine says Ophthalmologists don’t agree on uveitis naming/ethology & worse - Rheums & eye specialists don’t speak language. Need to know infections are r/o (syphillis, CXR) & if active uveitis to ⬆️Rx #ACR21 @RheumNow https://t.co/7LkhJnUKXK
Janet Pope @Janetbirdope( View Tweet )
Nov 06, 2021
@DrDDRheum presents on uveitis in SpA. AxSpA>PsA, 30% vs 7.6%. PsA: B27+⬆️ risk, smoking ⁉️ and DMARDs protective. AxSpA: Elevated CRP⬆️ risk, biologics protective. Abstr#0064 #ACR21 @RheumNow https://t.co/psw20RGDst
Richard Conway @RichardPAConway( View Tweet )
Nov 06, 2021
ICYMI: Risk of anterior uveitis w/ secukinumab is equal to etanercept; but both inferior to mAb TNFi (infliximab, adalimumab) ~ 5000 Rx starts, AU risk/100PY = SEC 6.8; ETA 7.5; INFLIX 2.9; ADA 4. SEC has a 2.3 fold greater risk than ADA/INFX https://t.co/DB9G2mz4mN https://t.co/91FbwCYsmj

Links:

Dr. John Cush @RheumNow( View Tweet )
Oct 17, 2021
RheumNow Podcast square

RheumNow Podcast – Quackademia (10.15.2021)

Jack Cush, MD
Oct 14, 2021

Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.

Read Article
Prescribe antimalarial dosages at 5 mg/kg/d or less.... A baseline retinal exam w/ optical coherence tomography should be performed w/in 6 mos...to rule out confounding Dz. Pts at low risk for retinopathy do not require annual screening until 5 years.. https://t.co/l3sCxOJLNJ

Links:

Dr. John Cush @RheumNow( View Tweet )

Sep 24, 2021
500 Turkish pts from 4 pediatric rheum clinics. Oligoart. JIA (oJIA) was most common (39%), then enthesitisJIA (ERA-23%), RF neg polyarthritis (16%), RF+ poly (2.2%), Systemic JIA (16%), juvenile PsA (5.2%). Uveitis most common in oJIA (13%), then ERA (5%) https://t.co/a7O1RBM1xJ https://t.co/woSafvVsmA

Links:

Dr. John Cush @RheumNow( View Tweet )
Sep 04, 2021
ICYMI: One of our top June videos WATCH: Is blindness with Tocilizumab in GCA a worry? Dr. David Liew ( @drdavidliew ) weighs in. #EULAR2021 https://t.co/eFrmbkW9Gy https://t.co/4tY3hEDj2j

Links:

Dr. John Cush @RheumNow( View Tweet )
Aug 01, 2021
Top 10 things you should know about THE EYE in your rheumatology practice @CRASCRRheum #uveitisclinic #uveitisrheumatologyclinic #kensingtoneyeinstitute https://t.co/SqRKOYa2N0
Vanessa Ocampo - MD @DrDDRheum( View Tweet )
Jul 27, 2021

Recent Blogs

My Take on New Ocular Screening Guidelines for Plaquenil

Sergio Schwartzman, MD
Oct 14, 2016
eye%20exa.jpg (keep)
A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).Read Post

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2022 All Rights Reserved.

×